Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company specializing in biomarker and augmented intelligence solutions for chronic low back pain, today announced the appointment of Daniel Keefe as Commercial Director for the Western United States. Keefe will lead commercial efforts in the region, building on Aclarion's existing footprint and supporting continued adoption of the company's Nociscan platform.
Nociscan is the first evidence-supported, cloud-based platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine. The platform uses magnetic resonance spectroscopy data from an MRI machine, proprietary signal processing techniques, and augmented intelligence algorithms to quantify chemical biomarkers associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, with a reported 97% surgical success rate when all Nociscan-positive discs are treated.
With an estimated 266 million people worldwide living with chronic low back pain, the condition remains one of the most pervasive health challenges. Aclarion's appointment of Keefe comes as the company reports triple-digit growth in Nociscan utilization, reflecting increasing demand for objective diagnostic tools in spine care. The Western U.S. has been a strategic region for Aclarion, with engagement spanning academic institutions and high-volume private practice spine centers.
“Dan brings a proven track record of driving commercial growth and expanding adoption of innovative surgical technologies,” said Brent Ness, Chief Executive Officer of Aclarion. “His deep experience working with spine surgeons and hospital systems, combined with his ability to build and scale high-performing territories, will be instrumental as we continue to grow our presence in the Western U.S. and support broader clinical use of Nociscan.”
Keefe joins Aclarion with more than 20 years of experience in medical device and healthcare technology sales, including leadership roles at Centinel Spine, Brainlab, Zimmer Biomet, and Intuitive Surgical. Most recently, he served as Regional Sales Manager at Centinel Spine, where he consistently exceeded performance targets and delivered significant year-over-year growth across the Northern California region. His career has focused on building strategic relationships with surgeons and hospital leadership, launching new technologies, and expanding market presence in competitive environments across spine, orthopedics, and image-guided surgery.
“I'm excited to join Aclarion at a time when Nociscan is gaining meaningful traction across the clinical community,” said Daniel Keefe, Commercial Director, Western U.S., Aclarion. “The ability to provide physicians with objective insight into the source of pain represents a significant advancement in how chronic low back pain is evaluated. I look forward to working with physicians and spine centers across the Western U.S. to expand access to Nociscan and support its continued integration into clinical practice.”
This appointment highlights Aclarion's focus on expanding commercialization and deepening adoption in key strategic regions. As the company continues to grow its presence, the addition of experienced commercial leaders like Keefe is expected to accelerate the integration of Nociscan into clinical workflows, potentially improving outcomes for millions of chronic low back pain sufferers. For more information on Nociscan, visit Aclarion's website or find a Nociscan center via their site map.
